AstraZeneca Says Camizestrant Reduces Risk Of Disease Progression By 56% In SERENA-6 Phase III Trial
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – AstraZeneca PLC (AZN) announced positive results from the SERENA-6 Phase III trial, demonstrating that camizestrant, in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor, significantly improved progression-free survival (PFS) in patients with hormone rece
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2148426264-ebbe5afc64f04238a9e94746f724e9a2.jpg "This Arizona Mountain Town Is One of the Most Expensive Places to Retire—Here’s Why")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1245437477-0eadd6a58fd84eee86413d2edfeb088b.jpg "<div>Greenfield vs. Brownfield Investments: What's the Difference?</div>")
:max_bytes(150000):strip_icc():format(jpeg)/LuisAlvarez-1127d045c8654052b3b8b9c77c9a6058.jpg)
" title=":max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2198966629-77b5074dcb594dafbac96b16cc878a78.jpg "<div>Should You Hire a Financial Advisor? Here's How to Know if You Need One</div>")
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-how-to-get-a-home-equity-line-of-credit-in-2023-7487051-a1ae78eaef704979816d093febbfceb5.jpg "The Real Cost of a Financial Advisor")